ClinicalTrials.gg

Program

opevesostat

Also written as “Opevesostat”, “MK-5684” and “ODM-208”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasms · Kidney Failure, Chronic, led by 2 companies.

Furthest: phase 3, since Nov 13, 202313 company-led studies, 5 open or runningNext primary completion: Nov 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck124 open or runningphase 3since Nov 13, 2023Oct 23, 2023Nov 4, 2027phase 2 · NCT06979596
Orion Corporation, Orion Pharma11 open or runningphase 2since Feb 12, 2018Feb 12, 2018none ahead
  • Named in Merck’s own pipeline as opevesostat (MK-5684), phase 3, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2018First study: phase 2 study in Prostate Cancer MetastaticNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT03436485 · 204 enrolled · United States, Finland, France and more
  2. Oct 23, 2023Merck's first study: phase 1 study in Prostatic NeoplasmsNew to MerckMerck · NCT06104449 · 7 enrolled · Japan
  3. Nov 13, 20232 phase 3 studiesMerck · NCT06136650, NCT06136624
  4. Nov 13, 2023Phase 1 study in Prostatic NeoplasmsMerck · NCT06136598 · 14 enrolled · China
  5. Apr 3, 2024Phase 2 study in Prostatic Neoplasms, Castration-ResistantMerck · NCT06353386 · 220 enrolled · United States, Australia, Canada and more
  6. Aug 12, 20242 phase 1 studies in Prostatic NeoplasmsMerck · NCT06554639, NCT06566989
  7. Oct 7, 2024Phase 1 study in HealthyMerck · NCT06633419 · 14 enrolled · United States
  8. Feb 3, 20252 phase 1 studiesMerck · NCT06814132, NCT06860243
  9. May 13, 2025Phase 2 study in NeoplasmsMerck · NCT06979596 · 250 planned · United States, Argentina, Brazil and more
  10. Apr 17, 2026Phase 1 study in HealthyMerck · NCT07548606 · 14 enrolled · United States
  11. Nov 5, 2026Primary completion moved from 2028-08-02 to 2028-11-30Date moved laterphase 3 · +4 months · NCT06136624

Ahead

  1. Nov 4, 2027Primary completion: phase 2 study in NeoplasmsMerck · NCT06979596
  2. May 10, 2028Primary completion: phase 3 study in Prostatic NeoplasmsMerck · NCT06136650
  3. Nov 30, 2028Primary completion: phase 3 study in Prostate Cancer MetastaticMerck · NCT06136624
  4. Jan 15, 2029Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantMerck · NCT06353386

TargetBeta

“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all ste…”NCIt, read by Claude
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), ”NCIt, by rule

Other programs on CYP11A1

ProgramCompanyFurthest phaseStudies
CYP11A1 Inhibitor ACE-232ruleacerand-therapeutics-hong-kong-limitedphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07548606Healthy · United States1CompletedMerckJun 1, 202614
NCT06979596Neoplasms · United States, Argentina, Brazil and more2RecruitingMerckNov 4, 2027250
NCT06860243Hepatic Impairment · United States1CompletedMerckFeb 9, 202616
NCT06814132Kidney Failure, Chronic · United States1CompletedMerckOct 4, 202524
NCT06633419Healthy · United States1CompletedMerckFeb 12, 202514
NCT06566989Prostatic Neoplasms · United Kingdom1CompletedMerckOct 17, 20248
NCT06554639Prostatic Neoplasms · United States1CompletedMerckAug 5, 202412
NCT06353386Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more2Active, not recruitingMerckJan 15, 2029220
NCT06136650Prostatic Neoplasms · United States, Australia, Brazil and more3RecruitingMerckMay 10, 20281,314
NCT06136624Prostate Cancer Metastatic · United States, Argentina, Australia and more3RecruitingMerckNov 30, 20281,310
NCT06136598Prostatic Neoplasms · China1CompletedMerckMar 9, 202614
NCT06104449Prostatic Neoplasms · Japan1CompletedMerckFeb 20, 20267
NCT03436485Prostate Cancer Metastatic · United States, Finland, France and more2Active, not recruitingOrion Corporation, Orion PharmaOct 31, 2026204

How it is read

Names in the registry

  • “Opevesostat”, 9 entries
  • “MK-5684”, 2 entries
  • “ODM-208”, 1 entry
  • “[¹⁴C]Opevesostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.